Podoplanin is a mucin-type protein with a mass of 36- to 43-kDa. It is relatively well conserved between species, with homologues in humans, mice, rats, dogs and hamsters.[4]
This gene encodes a type-I, integral membrane, heavily O-glycosylatedglycoprotein with diverse distribution in human tissues. The physiological function of this protein may be related to its mucin-type character. The homologous protein in other species has been described as a differentiation antigen and influenza-virus receptor. The specific function of this protein has not been determined but it has been proposed as a marker of lung injury. Alternatively spliced transcript variants encoding different isoforms have been identified.[3]
This protein has been found to have functions in lung alveolar cells, kidney podocytes, and lymphatic endothelial cells. More recently, this protein has been found in neural tissue in both mouse and human samples.[5]
In lymphatic endothelial cells, experimentation has indicated that podoplanin plays a role in proper formation of linkages between the cardiovascular system and the lymphatic systems, typically causing fatty liver disease in these mice.[5]
Although the exact function is unknown in many tissues, podoplanin is generally receptive to detection via immunofluorescent staining and has been shown to co-localize with the protein nestin, a type VI intermediate filament protein expressed almost primarily in neural tissues.[6] Currently, the only protein known to interact with podoplanin physiologically is CLEC-2, a C-type lectin 2 expressed on platelets and on hematopoietic cells.[7] Both serve a role in the proper formation of blood/lymphatic connections in embryonic development.
Clinical significance
PDPN has been studied extensively in the cancer field. It is a specific lymphatic vessel marker, and since lymphangiogenesis levels are correlated with poor prognosis in cancer patients, it can be used as a diagnostic marker.[4] It is often upregulated in certain types of cancer, including several types of squamous cell carcinomas, malignant mesothelioma and brain tumors.[4] Moreover, it can be upregulated by cancer-associated fibroblasts (CAFs) in the tumor stroma,[4][8] where it has been associated with poor prognosis.[9]
In squamous cell carcinomas, PDPN is believed to play a key role in the cancer cell invasiveness by controlling invadopodia, and thus mediating efficient ECM degradation.[10]
↑Ma T, Yang B, Matthay MA, Verkman AS (Jul 1998). "Evidence against a role of mouse, rat, and two cloned human t1alpha isoforms as a water channel or a regulator of aquaporin-type water channels". Am J Respir Cell Mol Biol. 19 (1): 143–9. doi:10.1165/ajrcmb.19.1.2953. PMID9651190.
Robertson NG, Khetarpal U, Gutiérrez-Espeleta GA, et al. (1995). "Isolation of novel and known genes from a human fetal cochlear cDNA library using subtractive hybridization and differential screening". Genomics. 23 (1): 42–50. doi:10.1006/geno.1994.1457. PMID7829101.
Cross SH, Charlton JA, Nan X, Bird AP (1994). "Purification of CpG islands using a methylated DNA binding column". Nat. Genet. 6 (3): 236–44. doi:10.1038/ng0394-236. PMID8012384.
Bonaldo MF, Lennon G, Soares MB (1997). "Normalization and subtraction: two approaches to facilitate gene discovery". Genome Res. 6 (9): 791–806. doi:10.1101/gr.6.9.791. PMID8889548.
Kato Y, Fujita N, Kunita A, et al. (2004). "Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors". J. Biol. Chem. 278 (51): 51599–605. doi:10.1074/jbc.M309935200. PMID14522983.
Kaneko M, Kato Y, Kunita A, et al. (2004). "Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/Podoplanin) molecules expressed in Chinese hamster ovary cells". J. Biol. Chem. 279 (37): 38838–43. doi:10.1074/jbc.M407210200. PMID15231832.
Martín-Villar E, Scholl FG, Gamallo C, et al. (2005). "Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas". Int. J. Cancer. 113 (6): 899–910. doi:10.1002/ijc.20656. PMID15515019.
Otsuki T, Ota T, Nishikawa T, et al. (2007). "Signal sequence and keyword trap in silico for selection of full-length human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA libraries". DNA Res. 12 (2): 117–26. doi:10.1093/dnares/12.2.117. PMID16303743.
Dumoff KL, Chu CS, Harris EE, et al. (2006). "Low podoplanin expression in pretreatment biopsy material predicts poor prognosis in advanced-stage squamous cell carcinoma of the uterine cervix treated by primary radiation". Mod. Pathol. 19 (5): 708–16. doi:10.1038/modpathol.3800580. PMID16528371.
Omachi T, Kawai Y, Mizuno R, et al. (2007). "Immunohistochemical demonstration of proliferating lymphatic vessels in colorectal carcinoma and its clinicopathological significance". Cancer Lett. 246 (1–2): 167–72. doi:10.1016/j.canlet.2006.02.013. PMID16574316.
Mishima K, Kato Y, Kaneko MK, et al. (2007). "Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression". Acta Neuropathol. 111 (5): 483–8. doi:10.1007/s00401-006-0063-y. PMID16596424.
Wicki A, Lehembre F, Wick N, et al. (2006). "Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton". Cancer Cell. 9 (4): 261–72. doi:10.1016/j.ccr.2006.03.010. PMID16616332.
Gregory SG, Barlow KF, McLay KE, et al. (2006). "The DNA sequence and biological annotation of human chromosome 1". Nature. 441 (7091): 315–21. doi:10.1038/nature04727. PMID16710414.
Mishima K, Kato Y, Kaneko MK, et al. (2007). "Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma". Acta Neuropathol. 111 (6): 563–8. doi:10.1007/s00401-006-0033-4. PMID16718353.